HER3 in cancer: from the bench to the bedside
Abstract The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implicate that targeting HER3 may have therapeutic relevance. Furthermore, expression and...
Main Authors: | Lucía Gandullo-Sánchez, Alberto Ocaña, Atanasio Pandiella |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-022-02515-x |
Similar Items
-
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01) -
Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01) -
Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation
by: Raphael Trenker, et al.
Published: (2024-03-01) -
Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer—A Single-Center Experience
by: Ramona Coca, et al.
Published: (2024-08-01) -
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart
by: Giannoula Lakka Klement, et al.
Published: (2012-06-01)